{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:story:973b8430-7752-4e5f-87ec-409ca4896747", "type": "composite", "version": "1", "versioncreated": "2026-11-22T14:15:18.501664Z", "firstcreated": "2026-11-22T14:15:18.501664Z", "pubstatus": "usable", "language": "uk", "headline": "Vertex досягла понад 70% успішності клінічних випробувань завдяки меншій кількості ставок", "description_text": "Виконавчий голова Vertex Pharmaceuticals Джефф Лейден пояснює, що компанія відмовилася від розпорошених інвестицій і зосередилася на перевірених біологічних мішенях, що дозволило їй досягти успішності випробувань понад 70% проти 10–20% у галузі.", "associations": {"item-0": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:756b8f9f-c01d-4b34-9eea-663951f1eb4d", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-11-22T14:15:42.732688Z", "firstcreated": "2026-11-22T14:15:18.501664Z", "pubstatus": "usable", "urgency": 5, "language": "uk", "headline": "Vertex досягла понад 70% успішності клінічних випробувань завдяки меншій кількості ставок", "byline": "Зоряна Яремчук", "located": "Ukraine", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Карторг", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Карторг”. Set rel=canonical to https://cartorg.com.ua/biznes/vertex-dosiagla-ponad-70-uspishnosti-klinichnikh-viprobuvan-zavdiaki-menshii-kilkosti-stavok/ when publishing on the web.", "description_text": "Виконавчий голова Vertex Pharmaceuticals Джефф Лейден пояснює, що компанія відмовилася від розпорошених інвестицій і зосередилася на перевірених біологічних мішенях, що дозволило їй досягти успішності випробувань понад 70% проти 10–20% у галузі.", "altids": {"mosaic": "756b8f9f-c01d-4b34-9eea-663951f1eb4d", "story": "973b8430-7752-4e5f-87ec-409ca4896747", "slug": "vertex-dosiagla-ponad-70-uspishnosti-klinichnikh-viprobuvan-zavdiaki-menshii-kilkosti-stavok"}, "subject": [{"name": "Economy and business", "rel": "direct", "literal": "economy", "code": "medtop:04000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/04000000"}], "place": [{"name": "Ukraine", "literal": "ua", "code": "UA", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:a430a7fd-1be4-47a3-91a8-cf1a0ea49410", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%", "description_text": "Vertex досягла понад 70% успішності клінічних випробувань завдяки меншій кількості ставок", "copyrightholder": "fortune.com", "copyrightnotice": "Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%", "usageterms": "Picture belongs to the source publication: address and terms are delivered, the file is not.", "altids": {"wireva": "a430a7fd-1be4-47a3-91a8-cf1a0ea49410"}, "extra": {"wireva:delivery_mode": "link_only", "wireva:rights": {"licence": "", "licence_url": "", "licence_raw": "RSS source", "licence_verified_at": "2026-11-22T14:15:42.817912Z", "attribution_required": true, "attribution_text": "Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "fortune.com", "source_url": "https://fortune.com/img-assets/wp-content/uploads/2026/11/jeffrey-leiden_6ea868.jpg?w=2048", "source_page_url": "https://fortune.com/img-assets/wp-content/uploads/2026/11/jeffrey-leiden_6ea868.jpg?w=2048", "our_page_url": "https://cartorg.com.ua/biznes/vertex-dosiagla-ponad-70-uspishnosti-klinichnikh-viprobuvan-zavdiaki-menshii-kilkosti-stavok/"}, "wireva:role": "lead"}, "renditions": {"source": {"href": "https://fortune.com/img-assets/wp-content/uploads/2026/11/jeffrey-leiden_6ea868.jpg?w=2048", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:973b8430-7752-4e5f-87ec-409ca4896747", "slug": "vertex-70-20261122", "status": "developing", "languages": ["uk"], "item_count": 1, "is_breaking": false}, "wireva:rights": {"class": "agency_original", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Карторг", "canonical_required": true, "canonical_url": "https://cartorg.com.ua/biznes/vertex-dosiagla-ponad-70-uspishnosti-klinichnikh-viprobuvan-zavdiaki-menshii-kilkosti-stavok/", "linkback_required": true, "licence": "Wireva subscriber licence", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "agency_original_verified", "needs_review": false}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "single_source", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "Матеріал підготовлено за допомогою ШІ під редакційною відповідальністю Haydamax OÜ.", "independence_check": {"status": "passed", "score": 0.026, "checked_at": "2026-11-22T14:15:42.804947Z"}, "sources": [{"url": "https://fortune.com/2026/11/22/vertex-leiden-rd-success-rate-fewer-smarter-bets-innovation/", "title": "Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%", "publisher": "fortune.com", "type": "rss", "role": "primary", "official": false, "retrieved_at": "2026-11-22T14:15:42.752206Z", "published_at": "2026-11-22T12:30:00Z"}]}, "wireva:publication": {"name": "Карторг", "domain": "cartorg.com.ua", "country": "UA", "url": "https://cartorg.com.ua/biznes/vertex-dosiagla-ponad-70-uspishnosti-klinichnikh-viprobuvan-zavdiaki-menshii-kilkosti-stavok/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/756b8f9f-c01d-4b34-9eea-663951f1eb4d", "html": "https://wireva.mib.news/item/756b8f9f-c01d-4b34-9eea-663951f1eb4d/vertex-dosiagla-ponad-70-uspishnosti-klinichnikh-viprobuvan-zavdiaki-menshii-kilkosti-stavok/", "story": "https://wireva.mib.news/story/vertex-70-20261122/"}, "wireva:metrics": {"word_count": 605, "char_count": 4483, "reading_time_seconds": 320}}}}, "extra": {"wireva:languages": ["uk"], "wireva:status": "developing", "wireva:item_count": 1}}